24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
24 Month Open Label Study of the Tolerability and Efficacy of an Antisense Oligonucleotide (Inotersen) in Patients With Transthyretin (TTR) Amyloid Cardiomyopathy
Sponsor: Brigham and Women's Hospital
Terminated
recruitment of new patients not possible during Covid 19 epidemic
Other terminated trials from Brigham and Women's Hospital
Other Amyloidosis trials with similar outcome
A PHASE2 clinical study on Amyloidosis, this trial is terminated or withdrawn. The trial is conducted by Brigham and Women's Hospital and has accumulated 7 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .